Deep Learning From Routine Histology Improves Risk Stratification for Biochemical Recurrence in Prostate Cancer

2026-03-14

AI Summary

Current clinicopathological models struggle to fully exploit prognostic information from routine hematoxylin and eosin (H&E)-stained whole-slide images of prostatectomy specimens, leading to suboptimal prediction of postoperative biochemical recurrence risk. This study proposes an end-to-end deep learning model that directly extracts subtle histomorphological features from whole-slide images—features not captured by conventional scoring systems such as CAPRA-S—to enable personalized, continuous recurrence risk prediction. By integrating these learned features with CAPRA-S, the model significantly enhances risk stratification. Validated across multiple international, independent multicenter cohorts, the approach improves the concordance index (C-index) of CAPRA-S from 0.725–0.772 to 0.749–0.788, demonstrating both strong generalizability and interpretability.

Technology Category

• Machine Learning: Feature Construction/Reformulation
• Reasoning under Uncertainty: Relational Probabilistic Models
• Computer Vision: Multi-modal Vision

Application Category

• Search and Retrieval-Augmented AI: Web evaluation methodologies and metrics
• User Modeling, Personalization and Recommendation: Fairness-aware retrieval and ranking
• Graph Algorithms and Modeling for the Web: Graph neural networks and deep learning approaches for Web-related graphs

Abstract

Accurate prediction of biochemical recurrence (BCR) after radical prostatectomy is critical for guiding adjuvant treatment and surveillance decisions in prostate cancer. However, existing clinicopathological risk models reduce complex morphology to relatively coarse descriptors, leaving substantial prognostic information embedded in routine histopathology underexplored. We present a deep learning-based biomarker that predicts continuous, patient-specific risk of BCR directly from H&E-stained whole-slide prostatectomy specimens. Trained end-to-end on time-to-event outcomes and evaluated across four independent international cohorts, our model demonstrates robust generalization across institutions and patient populations. When integrated with the CAPRA-S clinical risk score, the deep learning risk score consistently improved discrimination for BCR, increasing concordance indices from 0.725-0.772 to 0.749-0.788 across cohorts. To support clinical interpretability, outcome-grounded analyses revealed subtle histomorphological patterns associated with recurrence risk that are not captured by conventional clinicopathological risk scores. This multicohort study demonstrates that deep learning applied to routine prostate histopathology can deliver reproducible and clinically generalizable biomarkers that augment postoperative risk stratification, with potential to support personalized management of prostate cancer in real-world clinical settings.

Problem

• biochemical recurrence
• prostate cancer
• risk stratification
• histopathology
• prognostic biomarker

Innovation

• deep learning
• histopathology
• risk stratification
• biochemical recurrence
• prostate cancer